🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 17 horas
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
06/08/2015 10,72 10,96 10,64 10,71 -2,37% 2,99% 5.403
05/08/2015 10,91 11,03 10,72 10,97 -0,63% 2,84% 604
04/08/2015 10,86 11,09 10,85 11,04 +0,36% 2,21% 2.642
03/08/2015 11,00 11,29 11,00 11,00 -0,09% 2,64% 5.231
31/07/2015 11,05 11,26 10,70 11,01 +0,09% 5,07% 3.682
30/07/2015 11,00 11,30 10,89 11,00 +3,29% 3,73% 31.437
29/07/2015 10,95 10,95 10,65 10,65 -1,93% 2,74% 1.308
28/07/2015 10,97 10,97 10,70 10,86 +1,02% 2,46% 862
27/07/2015 11,05 11,05 10,72 10,75 -2,45% 2,99% 1.713
24/07/2015 11,08 11,18 10,96 11,02 -0,36% 1,99% 6.068
23/07/2015 11,10 11,21 11,04 11,06 -1,34% 1,53% 6.455
22/07/2015 11,61 11,67 11,20 11,21 -3,78% 4,05% 20.947
21/07/2015 11,46 11,71 11,46 11,65 +1,66% 2,18% 7.427
20/07/2015 11,70 11,70 11,02 11,46 -0,61% 5,81% 6.088
17/07/2015 11,74 11,75 11,52 11,53 -1,37% 1,96% 6.337
16/07/2015 11,05 11,75 11,00 11,69 +6,27% 6,79% 32.176
15/07/2015 10,70 11,00 10,70 11,00 +2,80% 2,80% 11.270
14/07/2015 10,89 10,89 10,70 10,70 -1,83% 1,74% 410
13/07/2015 10,84 11,00 10,84 10,90 +0,46% 1,48% 1.585
10/07/2015 11,00 11,00 10,62 10,85 -1,99% 3,45% 2.563
09/07/2015 10,73 11,15 10,73 11,07 +5,53% 3,91% 4.051
08/07/2015 10,61 10,75 10,49 10,49 -0,10% 2,45% 2.795
07/07/2015 10,22 10,50 10,22 10,50 +3,65% 2,74% 2.185
06/07/2015 10,20 10,20 10,13 10,13 -0,98% 0,69% 942
03/07/2015 10,33 10,33 10,23 10,23 -0,20% 0,97% 983
02/07/2015 10,25 10,36 10,22 10,25 -0,10% 1,37% 3.803
01/07/2015 10,24 10,37 10,22 10,26 +0,29% 1,46% 2.055
30/06/2015 10,22 10,38 10,22 10,23 -0,68% 1,57% 1.136
29/06/2015 10,05 10,48 10,05 10,30 -3,29% 4,28% 9.126
26/06/2015 10,95 11,19 10,58 10,65 -3,18% 5,57% 13.755